MedWatch

Novo’s new hope beats rivals on blood glucose and weight reduction

Semaglutide, the major hope in Novo Nordisk's pipeline, continues to outperform rival drugs in clinical trials and a new analysis, presented on the diabetes congress EASD in Lisbon, supports the potential of the drug.

Foto: Torben Åndahl

Expectations are high for Novo Nordisk’s experimental once-weekly GLP-1 analogue semaglutide, which could potentially enter the market next year.

The candidate has already shown excellent results in a range of clinical trials in the so-called Sustain program and now, a new analysis of five of those studies shows that semaglutide is outperforming other drugs when it comes to reducing both weight and long-term blood glucose (HbA1c).

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier